Full Press Release Details
Pieris Pharmaceuticals, Inc.
27th Annual Oppenheimer Healthcare Conference
Stephen Yoder, President & CEO
Statements in this presentation that are not descriptions of historical facts are
forward-looking statements that are based on management s current expectations and assumptions and are subject to risks and uncertainties. In some cases, you can identify forward-looking statements by terminology including
anticipates, believes, can, continue, could, estimates, expects, intends, may, plans, potential,
predicts, projects, should, will, would or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently
anticipated include, without limitation, risks relating to the results of our research and development activities, including uncertainties relating to the discovery of potential drug candidates and the preclinical and clinical testing of our drug
candidates; the early stage of our drug candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of our current drug candidates and any of our other future drug candidates; our need for substantial
additional funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we need; our future financial performance; our ability to retain or hire key scientific or management personnel; our ability to
protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights; our dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other
potential collaborators; our ability to successfully market and sell our drug candidates in the future as needed; the size and growth of the potential markets for any of our approved drug candidates, and the rate and degree of market acceptance of
any of our approved drug candidates; developments and projections relating to our competitors and our industry; our ability to establish collaborations; our expectations regarding the time which we will be an emerging growth company under the JOBS
Act; our use of proceeds from this offering; regulatory developments in the U.S. and foreign countries; and other factors that are described more fully in our Annual Report on form 10-K filed with the SEC on March 23, 2016. In light of these
risks, uncertainties and assumptions, the forward-looking statements regarding future events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the
forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this presentation speak only as of the date hereof, and except as required by law, we
undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.
the Playing Field for
Therapeutic Proteins
Anticalins A Novel Therapeutic Protein Drug Class
Class Fully proprietary and unique
Multiple Paths for Success & Risk Diversification
Novel Modes of Action Potentially transformative immuno-oncology multispecifics PRS-343
- TME-targeted T cell agonists / Multi-checkpoint blockade
Inhaled biologics may bring enormous benefits in respiratory disease PRS-060
Partnerships and Capital to Pursue Clinical-based Inflection Points
Validation and Growth Transformative alliance with Servier in Immuno-oncology with fully retained US rights
Capital on several novel multispecific drug candidates for immuno-oncology
Diversified Immuno-Oncology (IO) and Non-IO Product Pipeline
IMMUNO?ONCOLOGY PROGRAMS
Our Commercial Preclinical IND?
Candidate Target Indication Partner
Discovery Phase I Phase Ib/IIa
PRS?343 Bispecific IO Worldwide 4?1BB/GPC3 PRS?342 IO Worldwide Bispecific
PRS?300s n.d. IO Worldwide
PRS?332 Bispecific IO
U.S. Servier n.d./n.d. U.S./ Milestones Bispecific IO
4 Programs & Royalties
RESPIRATORY, ANEMIA AND OTHER DISEASE AREAS
Our Commercial Preclinical IND?
Candidate Target Indication
Partner Discovery Phase I Phase Ib/IIa
PRS?080 Hepcidin Anemia ex?Japan PRS?060 IL4Ra Asthma Worldwide
Milestones & DS?9001 PCSK9 Dyslipidemia Royalties Milestones & Daiichi Sankyo n.d.
n.d. Royalties Infectious Milestones & Sanofi P. aeruginosa disease Royalties PRS?110 cMet Oncology Major Markets
Experiencing an Acceleration Phase
Continued exploration of additional
Recent Value Drivers partnerships
ntry of inhaled respiratory program, 2017 PRS-060
Near-Term Value Drivers Strategic, Multi-program
Co-development IO Alliance 2017
rights on 4 programs Presentation of 2017
or Key data readout anemia program, (Hb) for PRS-080 2015 PRS-080
First IO Partnership
Focus on IO Clinical entry of Multispecifics and fully proprietary IO
Inhaled Biologics for program, PRS-343
2010-2011 Respiratory Disease 2015-2016
Multiple Large Lead IO and
Pharma Collaborations
Respiratory Programs 2017 IND-enabling Studies Partnership for PRS-080 in Japan 2014-2015
2001 Set up Boston HQ $25M Series B
Founded in led by OrbiMed Munich, Germany
Platform Improvements First Anticalin Initial drug enters clinic discovery efforts
The Early Years Drug Class Validation Acceleration Phase Disease Focus
2001 2007 2008 2013 2014 2016 2017+
Immuno-Oncology Partnership is a Transformative Strategic Alliance
Strategic Alliance Highlights
- Potential to expand to 3 additional bispecific programs
- Full US commercial rights on PRS-332 and up to 3 additional programs
Strategic Implications of Partnership
Partnership with ASKA Derisks and Accelerates Development of PRS-080
Alliance Highlights ASKA Company Overview
- Market Cap: ~$470M1
- Additional Milestones in other indications
Urology & Woman s Health and other Asian countries
Strategic Implications of Partnership
1: as of Feb 24, 2017
Anticalins Share Several Features with mAbs yet are Highly Differentiated
? Monoclonal Antibodies (mAbs) are highly successful drugs
? Anticalins share many of the beneficial properties of mAbs yet are highly differentiated
Differentiating Features
Natural binding molecule ? ? Non-immunogenic ? ? High affinity and specificity ? ? Systemic delivery ? ? Tunable pharmacokinetics (?) ? Valent- and geometry-versatile multispecifics ? Inhalable ? Protein class exclusivity ? Positive freedom to
operate landscape ? Safety Related Efficacy Related IP Related
and Geometry-Versatile Multi-specifics to Achieve Optimal Biology
Pure Anticalins Multispecif
ic Fc-Anticalins Building bloc
? Potent Multi-target Engagement ?Novel MoA ? Excellent Drug-like Properties
a First-in-Class TME-activated Co-stim Agonist
4-1BB (CD137) Key Costimulatory Target Tumor-specific T
? Marker for tumor-specific T cells in TME? Ameliorates T cell exhaustion? Critical for T cell expansion?
Induces anti-tumor cytolytic activity? Drives central memory T cell
differentiation for sustained response TcR
HER2 Strongly Validated Tumor Target
Restricted expression on normal tissue
? Multiple HER2+ tumors with high-unmet need? Breast,
Gastric & Bladder; several others? Mediates drug mobilization and immune receptor activation within the tumor bed
a First-in-Class TME-activated Co-stim Agonist
Engages HER2 on Tumor Cells
PRS-343 binds to HER2 expressed on tumor cells
a First-in-Class TME-activated Co-stim Agonist